Rein Therapeutics
RNTX
33 hedge funds and large institutions have $5.86M invested in Rein Therapeutics in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4.17% less ownership
Funds ownership: 35.33% → 31.16% (-4.2%)
11% less funds holding
Funds holding: 37 → 33 (-4)
30% less capital invested
Capital invested by funds: $8.34M → $5.86M (-$2.49M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$16.5K |
| 2 |
Renaissance Technologies
New York
|
+$15.9K |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$13.4K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$10.6K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$5.12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$752K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$103K |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$72K |
| 4 |
KL
KCK Ltd
Hamilton,
Bermuda
|
-$42.2K |
| 5 |
TCA
Taconic Capital Advisors
New York
|
-$35K |
RNTX Hedge Fund Activity: Q3 2022 in Review
33 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q3 2022, worth a combined $5.86M — down 30% from $8.34M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of RNTX and 4 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 8 added.
The largest buyer was William Blair & Company, adding an estimated $16.5K. The largest seller was Ikarian Capital, exiting entirely with an estimated $752K sold.
- 33 institutional investors held Rein Therapeutics (RNTX) as of Q3 2022, down from 37 in Q2 2022.
- Funds reported $5.86M of Rein Therapeutics stock for Q3 2022, down 30% quarter-over-quarter.
- 4 funds opened new Rein Therapeutics positions in Q3 2022 and 7 closed out, a net change of -3 holders.
- The largest Rein Therapeutics buyer in Q3 2022 was William Blair & Company, an estimated $16.5K added.
- The largest Rein Therapeutics seller in Q3 2022 was Ikarian Capital, an estimated $752K sold.
Based on aggregated 13F filings for Q3 2022.